Reviva Pharmaceuticals Holdings (RVPH) Records 37% in 2026 So far [Yahoo! Finance]
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Company Research
Source: Yahoo! Finance
As of the market open on January 9, 2026, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has surged roughly 37% in 2026 so far, showcasing a strong share price momentum. However, at the same time, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is facing near-term regulatory challenges amid this share momentum, with the FDA recommending a second Phase 3 trial for brilaroxazine in schizophrenia. On December 23, 2025, the company saw H.C. Wainwright reiterate a ‘Buy' rating with a $4 price target. The firm described the FDA guidance as consistent with precedent in schizophrenia drug development, projecting regulatory submission in late 2027, with potential approval and launch in late 2028. Meanwhile, Roth Capital revisited Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) the following day, reducing its price target to $1.50, while reiterating a ‘Buy' rating, according to TheFly . The firm cited anticipated equity dilution required to fund the second Phase 3 study, estim
Show less
Read more
Impact Snapshot
Event Time:
RVPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVPH alerts
High impacting Reviva Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
RVPH
News
- Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in SchizophreniaGlobeNewswire
- Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $2.00 price target on the stock.MarketBeat
- Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum [Yahoo! Finance]Yahoo! Finance
- Reviva to Present at the Sachs 9th Annual Neuroscience Innovation ForumGlobeNewswire
- Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RVPH&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
RVPH
Earnings
- 11/13/25 - Beat
RVPH
Sec Filings
- 12/23/25 - Form 8-K
- 12/22/25 - Form SCHEDULE
- 12/19/25 - Form 4
- RVPH's page on the SEC website